Pages that link to "Q35689146"
Jump to navigation
Jump to search
The following pages link to Pharmacogenomics of proton pump inhibitors (Q35689146):
Displaying 50 items.
- Proton pump inhibitors for the treatment of patients with erosive esophagitis and gastroesophageal reflux disease: current evidence and safety of dexlansoprazole (Q26741015) (← links)
- Pharmacogenomics of Drug Metabolizing Enzymes and Transporters: Relevance to Precision Medicine (Q27692687) (← links)
- Lansoprazole Is Associated with Worsening Asthma Control in Children with the CYP2C19 Poor Metabolizer Phenotype (Q30300235) (← links)
- Phenotype-genotype analysis of CYP2C19 in Colombian mestizo individuals. (Q33290485) (← links)
- CYP2C19 and nongenetic factors predict poor responsiveness to clopidogrel loading dose after coronary stent implantation (Q33368192) (← links)
- Dexlansoprazole in the treatment of esophagitis and gastroesophageal reflux disease (Q33445961) (← links)
- Quadruple rescue therapy for Helicobacter pylori infection after two treatment failures (Q34774061) (← links)
- Elevated serum gastrin is associated with a history of advanced neoplasia in Barrett's esophagus (Q35116562) (← links)
- The role of trefoil factor family in apparently healthy subjects administrated gastroprotective agents for the primary prevention of gastrointestinal injuries from low-dose acetylsalicylic acid: a preliminary study (Q35209641) (← links)
- A Multicenter, Randomized, Open-Label, Pharmacokinetics and Safety Study of Pantoprazole Tablets in Children and Adolescents Aged 6 Through 16 Years With Gastroesophageal Reflux Disease (Q35308159) (← links)
- Independent and combined effects of environmental factors and CYP2C19 polymorphisms on the risk of esophageal squamous cell carcinoma in Fujian Province of China (Q35576753) (← links)
- Pharmacogenetics of antiretroviral therapy: genetic variation of response and toxicity (Q35873680) (← links)
- Toward individualized pharmaceutical care of East Asians: the value of genetic testing for polymorphisms in drug-metabolizing genes (Q35873687) (← links)
- Improving pharmacotherapy outcomes by pharmacogenomics: from expectation to reality? (Q36278015) (← links)
- Genotype and allele frequency of CYP2C19*17 in a healthy Iranian population (Q36469405) (← links)
- The effect of CYP2C19 polymorphisms on H. pylori eradication rate in dual and triple first-line PPI therapies: a meta-analysis (Q36545135) (← links)
- Clinical Application of CYP2C19 Pharmacogenetics Toward More Personalized Medicine (Q36580034) (← links)
- Treatment and dosing of Helicobacter pylori infection: when pharmacology meets clinic (Q36723844) (← links)
- The clinical role of genetic polymorphisms in drug-metabolizing enzymes (Q36840621) (← links)
- How May Proton Pump Inhibitors Impair Cardiovascular Health? (Q36892867) (← links)
- Treatment strategy to eradicate Helicobacter pylori infection: impact of pharmacogenomics-based acid inhibition regimen and alternative antibiotics (Q36979297) (← links)
- Functional polymorphisms in the CYP2C19 gene contribute to digestive system cancer risk: evidence from 11,042 subjects (Q37017860) (← links)
- Genotype-phenotype analysis of CYP2C19 in healthy saudi individuals and its potential clinical implication in drug therapy (Q37176949) (← links)
- Proton pump inhibitors: an update of their clinical use and pharmacokinetics (Q37235086) (← links)
- CYP2C19 genotypes in the pharmacokinetics/pharmacodynamics of proton pump inhibitor-based therapy of Helicobacter pylori infection. (Q37646785) (← links)
- Factors associated with residual gastroesophageal reflux disease symptoms in patients receiving proton pump inhibitor maintenance therapy (Q37714369) (← links)
- Clopidogrel pharmacogenetics: metabolism and drug interactions (Q37912178) (← links)
- Acid peptic diseases: pharmacological approach to treatment (Q37913063) (← links)
- Individualized therapy for gastroesophageal reflux disease: potential impact of pharmacogenetic testing based on CYP2C19. (Q38032920) (← links)
- A benefit-risk assessment of the use of proton pump inhibitors in the elderly (Q38196383) (← links)
- Influence of low-dose proton pump inhibitors administered concomitantly or separately on the anti-platelet function of clopidogrel. (Q39014375) (← links)
- Histology of symptomatic gastroesophageal reflux disease: is it predictive of response to proton pump inhibitors? (Q39241665) (← links)
- A Case of Refractory Gastric Cardia Ulcer in Which Marked Elevation of the Surrounding Mucosa was Observed During the Clinical Course (Q39245665) (← links)
- Investigation of pretreatment prediction of proton pump inhibitor (PPI)-resistant patients with gastroesophageal reflux disease and the dose escalation challenge of PPIs-TORNADO study: a multicenter prospective study by the Acid-Related Symptom Rese (Q39260588) (← links)
- Randomised clinical trial: a multicentre, double-blind, placebo-controlled study on the efficacy and safety of rabeprazole 5 mg or 10 mg once daily in patients with non-erosive reflux disease (Q39276657) (← links)
- Efficacy of tailored Helicobacter pylori eradication treatment based on clarithromycin susceptibility and maintenance of acid secretion (Q39496607) (← links)
- Prevention of gastric mucosal injury induced by anti-platelet drugs by famotidine. (Q39543475) (← links)
- Progressing Preemptive Genotyping of CYP2C19 Allelic Variants for Sickle Cell Disease Patients. (Q41642334) (← links)
- Pharmacogenomic testing: the case for CYP2C19 proton pump inhibitor gene-drug pairs (Q41706384) (← links)
- The frequency of CYP2C19 genetic polymorphisms in Russian patients with peptic ulcers treated with proton pump inhibitors (Q42424894) (← links)
- Randomized, open-label, multicentre pharmacokinetic studies of two dose levels of pantoprazole granules in infants and children aged 1 month through <6 years with gastro-oesophageal reflux disease (Q42608396) (← links)
- Pharmacokinetics of three proton pump inhibitors in Chinese subjects in relation to the CYP2C19 genotype (Q42677554) (← links)
- Interaction between clopidogrel and proton-pump inhibitors and management strategies in patients with cardiovascular diseases (Q42731681) (← links)
- Efficacy and Safety of Concomitant Use of Rabeprazole during Dual-antiplatelet Therapy with Clopidogrel and Aspirin after Drug-eluting Stent Implantation: A Retrospective Cohort Study (Q42783482) (← links)
- Impact of proton pump inhibitors on the effectiveness of clopidogrel after coronary stent placement: the clopidogrel Medco outcomes study (Q42961046) (← links)
- Single-dose, multiple-dose, and population pharmacokinetics of pantoprazole in neonates and preterm infants with a clinical diagnosis of gastroesophageal reflux disease (GERD). (Q43122470) (← links)
- Relationship between low-dose aspirin-induced gastric mucosal injury and intragastric pH in healthy volunteers (Q43293550) (← links)
- Pharmacogenomics-based tailored versus standard therapeutic regimen for eradication of H. pylori (Q44371256) (← links)
- Should the presence of polymorphisms of CYP2C19 enzymes influence the choice of the proton pump inhibitor for treatment of Helicobacter pylori infection? (Q44805919) (← links)
- CYP2C19 genotype is associated with symptomatic recurrence of GERD during maintenance therapy with low-dose lansoprazole (Q46101359) (← links)